Effects of carvedilol on renal function
- PMID: 1974513
- DOI: 10.1007/BF01409473
Effects of carvedilol on renal function
Abstract
A randomized, double-blind, placebo-controlled study was conducted to study the effects of acute and chronic administration of carvedilol in essential hypertension, with special emphasis on renal haemodynamics and function. Acute administration of a single dose of 50 mg carvedilol reduced systolic and diastolic blood pressure without inducing reflex tachycardia. Renal blood flow was preserved; accordingly, renal vascular resistance was significantly reduced. A significant reduction in the glomerular filtration rate and filtration fraction was observed. Plasma renin activity (PRA) and plasma aldosterone values were not changed. Chronic carvedilol treatment produced a significant fall in systolic and diastolic blood pressure, heart rate, PRA and plasma aldosterone. Renal blood flow, glomerular filtration rate and filtration fraction also remained unchanged; renal vascular resistance decreased significantly. It is concluded that carvedilol possesses definite antihypertensive and renal vasodilating properties, both acutely and after chronic treatment.
Similar articles
-
Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension.J Cardiovasc Pharmacol. 1987;10 Suppl 11:S130-6. J Cardiovasc Pharmacol. 1987. PMID: 2454359 Clinical Trial.
-
Effect of long-term carvedilol therapy on renal function in essential hypertension.J Cardiovasc Pharmacol. 1992;19 Suppl 1:S97-101. doi: 10.1097/00005344-199219001-00019. J Cardiovasc Pharmacol. 1992. PMID: 1378158
-
Carvedilol and the kidney.Clin Investig. 1992;70 Suppl 1:S127-31. doi: 10.1007/BF00207623. Clin Investig. 1992. PMID: 1350479 Review.
-
Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.Scand J Clin Lab Invest. 2002;62(2):97-104. doi: 10.1080/003655102753611717. Scand J Clin Lab Invest. 2002. PMID: 12004934 Clinical Trial.
-
A new molecule with vasodilating and beta-adrenoceptor blocking properties.J Cardiovasc Pharmacol. 1987;10 Suppl 11:S23-32. J Cardiovasc Pharmacol. 1987. PMID: 2454364 Review.
Cited by
-
Long-term hemodynamic effects of antihypertensive treatment.Clin Investig. 1992;70 Suppl 1:S58-64. doi: 10.1007/BF00207613. Clin Investig. 1992. PMID: 1350486
-
Carvedilol in hypertension treatment.Vasc Health Risk Manag. 2008;4(1):23-30. doi: 10.2147/vhrm.2008.04.01.23. Vasc Health Risk Manag. 2008. PMID: 18629377 Free PMC article. Review.
-
Antihypertensive profile of carvedilol.Clin Investig. 1992;70 Suppl 1:S43-52. doi: 10.1007/BF00207611. Clin Investig. 1992. PMID: 1350484 Review.
-
Do adrenergic alpha-antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta-analysis.ESC Heart Fail. 2022 Oct;9(5):2823-2839. doi: 10.1002/ehf2.14012. Epub 2022 Jul 27. ESC Heart Fail. 2022. PMID: 35894772 Free PMC article.
-
Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.Clin Investig. 1992;70 Suppl 1:S93-7. doi: 10.1007/BF00207618. Clin Investig. 1992. PMID: 1350491 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials